On Jan. 07, Bevers Denise divested U.S. $195,349 in shares of Kindred Biosciences Inc.. The Dir sold 39,069 shares at a price per share of $5.00. The transaction decreased this specific insider’s holdings to 143,835 shares worth around $0.72 million at present.
Guggenheim took its Kindred Biosciences Inc. [KIN] rating to the equivalent of a Neutral from a Buy,in a research note dated March 17, 2020. Other analysts also revised their coverage, with Guggenheim’s analysts downgrading the shares from “a Buy” rating to “a Neutral” rating in a research note to investors issued in mid March. Meanwhile, H.C. Wainwright had maintained its rating on KIN to the earlier “Buy” rating, in a research note produced for clients November 13, 2019. In addition, there was a downgrade from B. Riley FBR on July 16, 2019. The rater changed KIN from “a Buy” to “a Neutral”.
Is Kindred Biosciences Inc. [NASDAQ:KIN] a Good Buy Right Now?
It should be noted that KIN technical indicators for short, intermediate as well as long term progress have placed an overall average of 40% as Buy. The average signal changed from 8% Buy in the last week and compares with 88% Sell in the past month. Data from Kindred Biosciences Inc.’s Trend Spotter indicated that the signals were Strengthening. The stock current average is 0.28 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 0.22 million shares while the medium term average advocated for 50% Sell. The average long-term signal stands at 50% Buy and the 100-day average volume stands at 0.27 million shares.
KIN Price Performance
On Wall Street, Kindred Biosciences Inc. [NASDAQ:KIN] finished Friday’s session down -2.33% at $5.03. The stock went up to $5.2099 at the same session while its lowest single day price was $4.88. In the last five days, it saw a rise of about 16.71%, Kindred Biosciences Inc. shares gained by almost 16.71% since the beginning of the year. However, the share price has dropped to as low as -57.84% below its one year high. On 01/08/21, the company shares recorded $5.21, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $4.28. The company’s shares have declined by -48.78% in the past year. The 50-day SMA achieved is $4.03 while the 200-day SMA is $4.25. Volume gained to 0.29 million from 0.29 million in the previous session.
KIN Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 4.87 level, and in case of violation of this particular level, it will cause more drop to 4.71 level. On the upper level, 5.37 is still the key resistance. The stock may increase to the subsequent resistance at 5.20. The Relative Strength Index (RSI) pinned on the 14-day chart is 67.25, implying a neutral technical stance while the MACD stands at 0.48, meaning price will decrease in the next trading period. Percent R indicator moved to 14.11%, implying bullish price movement. Stochastic %K at 90.82% suggest selling the stock.
What is the short interest in Kindred Biosciences Inc.?
Short interest in the Kindred Biosciences Inc. stock has plunged, decreasing by 34490.0 shares to total 0.71 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 0.68 million, data from Yahoo Finance shows. The increase of 4.84% suggests the stock saw some increased bearish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 2.35% of the overall float for the stock.
Kindred Biosciences Inc.’s Biggest Shareholders: Who Owns Kindred Biosciences Inc. [KIN]?
Filings by Park West Asset Management LLC showed that the firm now holds a total of 6,628,757 shares or roughly 16.80% of the outstanding KIN shares. This means their shares have reduced by 0 from the 6,628,757 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, BlackRock Fund Advisors updated stake is worth $8,908,069. Details in the latest 13F filings reveal that Threadneedle Asset Management Ltd disposed off their -0.73% stake valued at $7,393,155 while The Vanguard Group, Inc. cut theirs at $7,332,222. During the last quarter, Threadneedle Asset Management Ltd liquidated -14,063 of its shares in Kindred Biosciences Inc. while The Vanguard Group, Inc. sold -10,220 shares. The Ariel Investments LLC’s holdings currently number 1,685,506 shares at $8478095.18. According to the firm’s last 13F report, Adage Capital Management LP shares in the company at filing stood at 1,675,000 shares, roughly $6,515,750.
KIN Earnings Forecast For The Current Quarter
Kindred Biosciences Inc. [KIN] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $1.05M and an earnings per share of -$0.29 for Dec 2020. Looking further ahead, the company is expected to report revenue of $5.27M at an EPS of -$0.18 for Mar 2021. The estimates represent downside of -57.50% and -32.80% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
KIN Earnings Estimates For The Current Year
For the financial year, Kindred Biosciences Inc. [NASDAQ:KIN] is expected to bring in revenue of $42.15M. The returns are nearly $37.89 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -0.58, higher than that of FY19 by $1.01. Estimates put this year’s earnings growth at 63.50%, -32.80% for the next, and at an annual 40.00% over the next 5-year period. As for sales, forecasts are for an increase of 890.40% in the current fiscal year and a further -57.50% over the following year.
What are analyst thoughts on Kindred Biosciences Inc.?
Looking forward to the Kindred Biosciences Inc. share price prediction, we can see that analysts, surveyed by FactSet, offer the mean price target for Kindred Biosciences Inc. stock at $10.50 within the next 12 months, which represents almost 52.1 per cent growth from its previous closing price of $5.03. The highest analysts’ target for Kindred Biosciences Inc. stock projections is $12.00 and the lowest one is $9.00. Still, 7 analysts sharing their consensus rating for KIN stock in 2021 agree that it is a Buy.